WO2002028844A1 - Dérivés thiazole ou oxazole - Google Patents

Dérivés thiazole ou oxazole Download PDF

Info

Publication number
WO2002028844A1
WO2002028844A1 PCT/JP2001/008507 JP0108507W WO0228844A1 WO 2002028844 A1 WO2002028844 A1 WO 2002028844A1 JP 0108507 W JP0108507 W JP 0108507W WO 0228844 A1 WO0228844 A1 WO 0228844A1
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
compounds
optionally substituted
thiazole
oxazole derivatives
Prior art date
Application number
PCT/JP2001/008507
Other languages
English (en)
French (fr)
Inventor
Fumihiko Watanabe
Yoshinori Tamura
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Priority to EP01972561A priority Critical patent/EP1331224A4/en
Priority to CA002423885A priority patent/CA2423885A1/en
Priority to US10/381,280 priority patent/US6949566B2/en
Priority to AU2001292285A priority patent/AU2001292285A1/en
Priority to KR10-2003-7004302A priority patent/KR20030030036A/ko
Priority to JP2002532429A priority patent/JPWO2002028844A1/ja
Publication of WO2002028844A1 publication Critical patent/WO2002028844A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
PCT/JP2001/008507 2000-09-29 2001-09-28 Dérivés thiazole ou oxazole WO2002028844A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01972561A EP1331224A4 (en) 2000-09-29 2001-09-28 THIAZOLE AND OXAZOLE DERIVATIVES
CA002423885A CA2423885A1 (en) 2000-09-29 2001-09-28 Thiazole and oxazole derivatives
US10/381,280 US6949566B2 (en) 2000-09-29 2001-09-28 Thiazole and oxazole derivatives
AU2001292285A AU2001292285A1 (en) 2000-09-29 2001-09-28 Thiazole or oxazole derivatives
KR10-2003-7004302A KR20030030036A (ko) 2000-09-29 2001-09-28 티아졸 또는 옥사졸 유도체
JP2002532429A JPWO2002028844A1 (ja) 2000-09-29 2001-09-28 チアゾールおよびオキサゾール誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000298199 2000-09-29
JP2000-298199 2000-09-29

Publications (1)

Publication Number Publication Date
WO2002028844A1 true WO2002028844A1 (fr) 2002-04-11

Family

ID=18780188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008507 WO2002028844A1 (fr) 2000-09-29 2001-09-28 Dérivés thiazole ou oxazole

Country Status (8)

Country Link
US (1) US6949566B2 (ja)
EP (1) EP1331224A4 (ja)
JP (1) JPWO2002028844A1 (ja)
KR (1) KR20030030036A (ja)
CN (1) CN1273456C (ja)
AU (1) AU2001292285A1 (ja)
CA (1) CA2423885A1 (ja)
WO (1) WO2002028844A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035610A1 (fr) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Derive de sulfonamide a effet inhibiteur sur les mmp
WO2003080041A1 (fr) * 2002-03-27 2003-10-02 Shionogi & Co., Ltd. Remede contre l'arthrite deformante
WO2004080452A1 (ja) * 2003-03-10 2004-09-23 Shionogi & Co., Ltd. 網膜疾患治療薬
WO2004092146A2 (en) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
EP1491190A1 (en) * 2002-03-27 2004-12-29 Shionogi & Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
WO2005012268A1 (ja) * 2003-07-30 2005-02-10 Shionogi & Co., Ltd. イソオキサゾール環を有するスルホンアミド誘導体
WO2007102392A1 (ja) 2006-03-03 2007-09-13 Shionogi & Co., Ltd. Ｍｍｐ－１３選択的阻害剤
US7358364B2 (en) 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted carboxylic acids
WO2008053913A1 (fr) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
WO2010112520A1 (en) 2009-04-01 2010-10-07 Novartis Ag Spiro derivatives for the modulation of stearoyl-coa desaturase

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005445A (es) * 2002-11-25 2005-08-26 Hoffmann La Roche Derivados de indolilo.
WO2006013209A2 (en) * 2004-08-02 2006-02-09 Genmedica Therapeutics Sl Compounds for inhibiting copper-containing amine oxidases and uses thereof
US20080119513A1 (en) * 2004-09-06 2008-05-22 Fumihiko Watanabe Sulfonamide Derivative Selectively Inhibiting Mmp-13
US20120129843A1 (en) * 2010-11-18 2012-05-24 Yan Zhang Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
US20120129872A1 (en) * 2010-11-18 2012-05-24 Kristi Anne Leonard Fused heteroaryl inhibitors of pro-matrix metalloproteinase activation
WO2012162461A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012162463A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757037A2 (en) * 1995-07-28 1997-02-05 Ono Pharmaceutical Co., Ltd. Sulfonylamino acid derivatives as metalloproteinase inhibitors
WO1999004780A1 (fr) * 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3628335B2 (ja) 1996-01-23 2005-03-09 塩野義製薬株式会社 スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤
SK282863B6 (sk) * 1996-05-17 2002-12-03 Warner-Lambert Company Bifenylsulfonamidy, ich použitie a farmaceutické prostriedky na ich báze
CN1349498A (zh) * 1999-03-03 2002-05-15 宝洁公司 含有链烯基和炔基的金属蛋白酶抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757037A2 (en) * 1995-07-28 1997-02-05 Ono Pharmaceutical Co., Ltd. Sulfonylamino acid derivatives as metalloproteinase inhibitors
WO1999004780A1 (fr) * 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1331224A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035610A1 (fr) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Derive de sulfonamide a effet inhibiteur sur les mmp
EP1491190A1 (en) * 2002-03-27 2004-12-29 Shionogi & Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
WO2003080041A1 (fr) * 2002-03-27 2003-10-02 Shionogi & Co., Ltd. Remede contre l'arthrite deformante
EP1491190A4 (en) * 2002-03-27 2006-01-04 Shionogi & Co DECOMPOSITION INHIBITOR FOR CARTRIDGE EXTRACELLULAR MATRIX
WO2004080452A1 (ja) * 2003-03-10 2004-09-23 Shionogi & Co., Ltd. 網膜疾患治療薬
JP2006524248A (ja) * 2003-04-14 2006-10-26 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 糖尿病の治療用のｎ−（（（（（１，３−チアゾール−２−イル）アミノ）カルボニル）フェニル）スルホニル）フェニルアラニン誘導体及び関連化合物
WO2004092146A3 (en) * 2003-04-14 2004-12-29 Inst For Pharm Discovery Inc N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
WO2004092146A2 (en) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
US7358364B2 (en) 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted carboxylic acids
WO2005012268A1 (ja) * 2003-07-30 2005-02-10 Shionogi & Co., Ltd. イソオキサゾール環を有するスルホンアミド誘導体
JPWO2005012268A1 (ja) * 2003-07-30 2006-09-14 塩野義製薬株式会社 イソオキサゾール環を有するスルホンアミド誘導体
US7825146B2 (en) 2003-07-30 2010-11-02 Shionogi & Co., Ltd. Sulfonamide derivative having isoxazole ring
WO2007102392A1 (ja) 2006-03-03 2007-09-13 Shionogi & Co., Ltd. Ｍｍｐ－１３選択的阻害剤
WO2008053913A1 (fr) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
WO2010112520A1 (en) 2009-04-01 2010-10-07 Novartis Ag Spiro derivatives for the modulation of stearoyl-coa desaturase

Also Published As

Publication number Publication date
US6949566B2 (en) 2005-09-27
EP1331224A4 (en) 2004-03-17
AU2001292285A1 (en) 2002-04-15
US20040024029A1 (en) 2004-02-05
CN1273456C (zh) 2006-09-06
JPWO2002028844A1 (ja) 2004-02-12
CA2423885A1 (en) 2003-03-27
KR20030030036A (ko) 2003-04-16
CN1466580A (zh) 2004-01-07
EP1331224A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
WO2002028844A1 (fr) Dérivés thiazole ou oxazole
EP1288199A4 (en) INHIBITORS OF MMP-12
WO2002057252A3 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
WO2001077107A8 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors
MY136685A (en) Thiazole derivatives for treating ppar related disorders
AU2002211216A1 (en) Substituted aminopropoxyaryl derivatives useful as agonists for lxr
DK1076663T3 (da) Funktionaliserede alkyl- og alkenylsidekædederivater af glycinamider som farnesyltransferaseinhibitorer
NO20013379D0 (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
CA2547947A1 (en) Azole derivatives as active superoxide radical inhibitors
CA2379747A1 (en) Novel succinate derivative compounds useful as cysteine protease inhibitors
EP1172361A4 (en) SULFONAMIDE DERIVATIVES HAVING OXADIAZOLE CORES
NO883487L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
NO20022125L (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
MX9800718A (es) Derivados de 2-(4-substituidos)-bencilamino-2-metil- propanamida.
WO1999000373A8 (fr) Derives de benzimidazole
AR012603A1 (es) Inhibidor de proteasa, composicion farmaceutica que lo comprende y el uso del mismo para la fabricacion de un medicamento; e intermediarios de sintesis
BG104575A (en) Matrix metalloprotease inhibitors
AU5758694A (en) Benzoxazine derivatives, their preparation, and their application in therapy
TW200505446A (en) Inhibitor of cox
EP1099690A4 (en) MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM
EP1270569A4 (en) SUBSTITUTED TRYPTOPHAN DERIVATIVES
WO2004099130A3 (en) 1,2-diarylimidazoles useful as inhibitors of cox
DE60019630D1 (de) 2-Fluoro-(oxido-Thiopyran-4-yl)Benzol Derivate
EP0516860A4 (en) Chromone derivative and aldose reductase inhibitor containing the same as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002532429

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10381280

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020037004302

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2423885

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 018164943

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037004302

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001972561

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001972561

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001972561

Country of ref document: EP